Article Text

Download PDFPDF
512 HPV genotyping for cervical cancer risk stratification in VIA based primary cervical cancer screening program in India
  1. Sharmila Pimple1,
  2. Tanuja Teni2,
  3. Gauravi Mishra1 and
  4. SAGAR Pawar2
  1. 1Centre For Cancer Epidemiology, Tata Memorial Centre, Mumbai, India
  2. 2ACTREC, Tata Memorial Centre, Navi Mumbai, India


Introduction/Background The national cervical cancer screening program in India recommends Visual Inspection with Acetic acid [VIA] as a primary screening test. Most screen positive women do not have clinically significant disease due to low specificity and positive predictive value of VIA test. Screening algorithms using genotype-specific risk stratification may allow for more precise colposcopy referral reducing overtreatment. Present study assessed the utility of HPV genotyping for the triage and risk stratification of cervical cancer screening .

Methodology Women in the age group of 25–65 years were screened with the primary screening test VIA. VIA test positive women were further offered secondary screening tests of HPV E6/E7 mRNA test and HPV genotyping. The reference standard for final disease status was Histopathology

Results Out of the total 1003 women tested positive on VIA primary screening test, 106 were [10.6%] were positive for HPV mRNA_E6_E7. Overall distribution of Single HPV Genotypes was ; HPV 16 [14.2], HPV 18 [15.1], HPV 31 [8.5], HPV 33 [6.6], HPV 45 [2.8]. Mixed Infection of HPV 16_31 was found in 50 [47.2%] followed by HPV 31_45 in 2 [1.9%]. For histologically confirmed CIN 2+ category lesions, percentage distribution of HPV genotypes in descending order was as follows, HPV16_31 [68.3% ], HPV 16 [14.6%], HPV 18 [4.9%], HPV 45 [4.9%], HPV 33 [2.4% ] and HPV 31 [ 0.00%]. When both 16 and 31 were positive the risk of developing malignancy was 3.818 [ Odds Ratio ] for CIN2 and above lesions .

Conclusion Mixed Infection of HPV 16 & 31 [47.2%] contributed to the highest burden of HPV positive infections. Multiple HPV genotype 16–31 was associated with 3.8 fold increase in the risk of developing malignancy. The study provides evidence for customizing the HPV Partial Genotyping Assays conforming to the High Risk pattern within the region.

Disclosures NONE.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.